Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

The phase I TRAVERSE trial evaluated allogeneic CD70-targeted CAR-T cell therapy in patients with advanced renal cell carcinoma, representing an early but notable step toward off-the-shelf CAR-T products in solid tumors. Results published in the Journal of Clinical Oncology establish initial safety and activity signals for this approach, though specific response rates and survival data require review of the full publication. Allogeneic CAR-T platforms are significant because they eliminate the need for patient-specific manufacturing, potentially broadening access and reducing costs compared to autologous products.